September 22, 2005

Binh Nguyen, M.D., Ph.D. named VP of Clinical Development and Regulatory Affairs of Tigris Pharmaceuticals

NEW YORK, September 22, 2005 - Tigris Pharmaceuticals, Inc., a development stage biopharmaceutical company, is pleased to announce the appointment of Binh Nguyen, M.D., Ph.D. as its Vice President of Clinical Development and Regulatory Affairs. Dr. Nguyen brings over 10 years of drug development experience in oncology.

"I am delighted to welcome Dr. Nguyen to Tigris' team. His extensive clinical development and regulatory experience will make him instrumental to our company's success as we continue to develop A-007 and as we expand our pipeline," said Dr. Edmundo Muniz, Tigris' President and Chief Executive Officer.

Dr. Nguyen has significant experience in oncology clinical drug development and regulatory affairs. Prior to joining Tigris, Dr. Nguyen served as Executive Director of the Oncology Platform Team and of the Pharmacogenomic Program for Eli Lilly and Company. In this role, Dr. Nguyen was responsible for the overall clinical development plan with correlated translational research of numerous early- and late-stage molecules. He managed interactions with regulatory authorities in the US, Europe, and Japan, and has successfully led two defenses at the Oncologic Drug Advisory Committee (ODAC) of the US Food and Drug Administration (FDA). He has achieved successful global approvals for two drugs in six indications (mesothelioma, 1st line and 2nd line non-small cell lung, pancreatic, bladder, breast and ovarian cancer).

Prior to his work with Eli Lilly, Dr. Nguyen completed his medical oncology fellowship at the National Cancer Institute and was a Clinical Fellow at the Cancer Therapy Evaluation Program (CTEP), where he was responsible for the clinical development plan of investigational drugs. Dr. Nguyen was also a fellow at the Center for Drug Evaluation and Research (CDER) at the Division of Pulmonary and Oncology Drug Products of the FDA, where he was responsible for reviewing Investigational New Drug (IND) and New Drug Application (NDA) filings.

Dr. Nguyen holds a Ph.D. in Organic Chemistry from Georgetown University, and he received his M.D. from the University of Maryland.

"Dr. Nguyen's hiring is a critical step toward Tigris' vision of becoming a premier biopharmaceutical therapeutics company through careful selection of high quality molecules, thoughtful growth of in-house expertise, and outsourcing partnerships," said Dr. Muniz. "Moving forward, we plan to leverage management's extensive drug development expertise and the agility of a lean, efficient organization."

About Tigris Pharmaceuticals, Inc.

Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that acquires the rights to commercially develop therapeutic technologies to address unmet medical needs. Tigris is currently developing a topical treatment for pre-cancerous and cancerous anogenital lesions associated with the human papillomavirus (HPV), which is expected to enter Phase II human clinical trials in late 2005. The company's mission is to efficiently move its existing and future technologies through the various stages of clinical development in order to meet patients' needs for safe and effective treatments of human illnesses.

Contact:

Edmundo Muniz
President and Chief Executive Officer
Tigris Pharmaceuticals, Inc.
info@tigrispharma.com

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, and product pricing and third party reimbursement. We undertake no obligation to update any forward-looking statement contained in this press release, except as required by law.